Previous close | 250.14 |
Open | 249.78 |
Bid | 0.00 x 800 |
Ask | 0.00 x 1000 |
Day's range | 247.35 - 256.01 |
52-week range | 200.32 - 290.20 |
Volume | |
Avg. volume | 671,308 |
Market cap | 22.592B |
Beta (5Y monthly) | 1.05 |
PE ratio (TTM) | 13.69 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 2.88 (1.15%) |
Ex-dividend date | 22 Feb 2023 |
1y target est | N/A |
BURLINGTON, N.C., January 18, 2023--Labcorp (NYSE: LH), a leading global life sciences company, will release its financial results for the fourth quarter and full year 2022 before the market opens on Thursday, Feb. 16, 2023. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website.
BURLINGTON, N.C., January 12, 2023--Labcorp (NYSE: LH), a leading global life sciences company, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on March 13, 2023, to stockholders of record as of the close of business on Feb. 23, 2023.
BURLINGTON, N.C., January 05, 2023--Labcorp (NYSE: LH), a leading global life sciences company, today announced that Thomas (Tom) Pike will join Labcorp as president and chief executive officer of its Drug Development Clinical Development business unit on Jan. 9, 2023. Until the planned spin-off of the Clinical Development business, which is expected to occur in mid-2023, Mr. Pike will report to Labcorp’s chairman and CEO Adam Schechter. At the time of the spin-off, Mr. Pike will serve as the ch